Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study
Identifieur interne : 002379 ( Main/Corpus ); précédent : 002378; suivant : 002380Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study
Auteurs : David Devos ; Kathy Dujardin ; Isabelle Poirot ; Caroline Moreau ; Olivier Cottencin ; Pierre Thomas ; Alain Destée ; Regis Bordet ; Luc DefebvreSource :
- Movement Disorders [ 0885-3185 ] ; 2008-04-30.
English descriptors
Abstract
Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD). Recent reviews have highlighted the lack of controlled trials and the ensuing difficulty in formulating recommendations for antidepressant use in PD. We sought to establish whether antidepressants provide real benefits and whether tricyclic and selective serotonin reuptake inhibitor (SSRI) antidepressants differ in their short‐term efficacy, because the time to onset of therapeutic benefit remains an important criterion in depression. The short‐term efficacy (after 14 and 30 days) of two antidepressants (desipramine, a predominantly noradrenergic reuptake inhibitor tricyclic and citalopram, a SSRI) was assessed in a double‐blind, randomized, placebo‐ controlled study of 48 nondemented PD patients suffering from major depression. After 14 days, desipramine prompted an improvement in the Montgomery Asberg Depression Rating Scale (MADRS) score, compared with citalopram and placebo. Both antidepressants produced significant improvements in the MADRS score after 30 days. Mild adverse events were twice as frequent in the desipramine group as in the other groups. A predominantly noradrenergic tricyclic antidepressant induced a more intense short‐term effect on parkinsonian depression than did an SSRI. However, desipramine's lower tolerability may outweigh its slight short‐term clinical advantage. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.21966
Links to Exploration step
ISTEX:06154D74D83A89BE5059BABDAB5AF0211C913E45Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study</title><author><name sortKey="Devos, David" sort="Devos, David" uniqKey="Devos D" first="David" last="Devos">David Devos</name><affiliation><mods:affiliation>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name><affiliation><mods:affiliation>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Poirot, Isabelle" sort="Poirot, Isabelle" uniqKey="Poirot I" first="Isabelle" last="Poirot">Isabelle Poirot</name><affiliation><mods:affiliation>Department of Neurophysiology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Moreau, Caroline" sort="Moreau, Caroline" uniqKey="Moreau C" first="Caroline" last="Moreau">Caroline Moreau</name><affiliation><mods:affiliation>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Cottencin, Olivier" sort="Cottencin, Olivier" uniqKey="Cottencin O" first="Olivier" last="Cottencin">Olivier Cottencin</name><affiliation><mods:affiliation>Department of Psychiatry, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Thomas, Pierre" sort="Thomas, Pierre" uniqKey="Thomas P" first="Pierre" last="Thomas">Pierre Thomas</name><affiliation><mods:affiliation>Department of Psychiatry, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Destee, Alain" sort="Destee, Alain" uniqKey="Destee A" first="Alain" last="Destée">Alain Destée</name><affiliation><mods:affiliation>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Bordet, Regis" sort="Bordet, Regis" uniqKey="Bordet R" first="Regis" last="Bordet">Regis Bordet</name><affiliation><mods:affiliation>Department of Pharmacology, IFR 114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Defebvre, Luc" sort="Defebvre, Luc" uniqKey="Defebvre L" first="Luc" last="Defebvre">Luc Defebvre</name><affiliation><mods:affiliation>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:06154D74D83A89BE5059BABDAB5AF0211C913E45</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/mds.21966</idno><idno type="url">https://api.istex.fr/document/06154D74D83A89BE5059BABDAB5AF0211C913E45/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002379</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study</title><author><name sortKey="Devos, David" sort="Devos, David" uniqKey="Devos D" first="David" last="Devos">David Devos</name><affiliation><mods:affiliation>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name><affiliation><mods:affiliation>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Poirot, Isabelle" sort="Poirot, Isabelle" uniqKey="Poirot I" first="Isabelle" last="Poirot">Isabelle Poirot</name><affiliation><mods:affiliation>Department of Neurophysiology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Moreau, Caroline" sort="Moreau, Caroline" uniqKey="Moreau C" first="Caroline" last="Moreau">Caroline Moreau</name><affiliation><mods:affiliation>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Cottencin, Olivier" sort="Cottencin, Olivier" uniqKey="Cottencin O" first="Olivier" last="Cottencin">Olivier Cottencin</name><affiliation><mods:affiliation>Department of Psychiatry, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Thomas, Pierre" sort="Thomas, Pierre" uniqKey="Thomas P" first="Pierre" last="Thomas">Pierre Thomas</name><affiliation><mods:affiliation>Department of Psychiatry, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Destee, Alain" sort="Destee, Alain" uniqKey="Destee A" first="Alain" last="Destée">Alain Destée</name><affiliation><mods:affiliation>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Bordet, Regis" sort="Bordet, Regis" uniqKey="Bordet R" first="Regis" last="Bordet">Regis Bordet</name><affiliation><mods:affiliation>Department of Pharmacology, IFR 114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Defebvre, Luc" sort="Defebvre, Luc" uniqKey="Defebvre L" first="Luc" last="Defebvre">Luc Defebvre</name><affiliation><mods:affiliation>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-04-30">2008-04-30</date><biblScope unit="volume">23</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="850">850</biblScope><biblScope unit="page" to="857">857</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">06154D74D83A89BE5059BABDAB5AF0211C913E45</idno><idno type="DOI">10.1002/mds.21966</idno><idno type="ArticleID">MDS21966</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>antidepressant treatment</term><term>depression</term><term>norepinephrine</term><term>serotonin</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD). Recent reviews have highlighted the lack of controlled trials and the ensuing difficulty in formulating recommendations for antidepressant use in PD. We sought to establish whether antidepressants provide real benefits and whether tricyclic and selective serotonin reuptake inhibitor (SSRI) antidepressants differ in their short‐term efficacy, because the time to onset of therapeutic benefit remains an important criterion in depression. The short‐term efficacy (after 14 and 30 days) of two antidepressants (desipramine, a predominantly noradrenergic reuptake inhibitor tricyclic and citalopram, a SSRI) was assessed in a double‐blind, randomized, placebo‐ controlled study of 48 nondemented PD patients suffering from major depression. After 14 days, desipramine prompted an improvement in the Montgomery Asberg Depression Rating Scale (MADRS) score, compared with citalopram and placebo. Both antidepressants produced significant improvements in the MADRS score after 30 days. Mild adverse events were twice as frequent in the desipramine group as in the other groups. A predominantly noradrenergic tricyclic antidepressant induced a more intense short‐term effect on parkinsonian depression than did an SSRI. However, desipramine's lower tolerability may outweigh its slight short‐term clinical advantage. © 2008 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>David Devos MD, PhD</name><affiliations><json:string>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</json:string></affiliations></json:item><json:item><name>Kathy Dujardin PhD</name><affiliations><json:string>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</json:string></affiliations></json:item><json:item><name>Isabelle Poirot MD</name><affiliations><json:string>Department of Neurophysiology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</json:string></affiliations></json:item><json:item><name>Caroline Moreau MD</name><affiliations><json:string>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</json:string></affiliations></json:item><json:item><name>Olivier Cottencin MD</name><affiliations><json:string>Department of Psychiatry, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</json:string></affiliations></json:item><json:item><name>Pierre Thomas MD, PhD</name><affiliations><json:string>Department of Psychiatry, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</json:string></affiliations></json:item><json:item><name>Alain Destée MD</name><affiliations><json:string>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</json:string></affiliations></json:item><json:item><name>Regis Bordet MD, PhD</name><affiliations><json:string>Department of Pharmacology, IFR 114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</json:string></affiliations></json:item><json:item><name>Luc Defebvre MD, PhD</name><affiliations><json:string>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>depression</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>antidepressant treatment</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>serotonin</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>norepinephrine</value></json:item></subject><articleId><json:string>MDS21966</json:string></articleId><language><json:string>eng</json:string></language><abstract>Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD). Recent reviews have highlighted the lack of controlled trials and the ensuing difficulty in formulating recommendations for antidepressant use in PD. We sought to establish whether antidepressants provide real benefits and whether tricyclic and selective serotonin reuptake inhibitor (SSRI) antidepressants differ in their short‐term efficacy, because the time to onset of therapeutic benefit remains an important criterion in depression. The short‐term efficacy (after 14 and 30 days) of two antidepressants (desipramine, a predominantly noradrenergic reuptake inhibitor tricyclic and citalopram, a SSRI) was assessed in a double‐blind, randomized, placebo‐ controlled study of 48 nondemented PD patients suffering from major depression. After 14 days, desipramine prompted an improvement in the Montgomery Asberg Depression Rating Scale (MADRS) score, compared with citalopram and placebo. Both antidepressants produced significant improvements in the MADRS score after 30 days. Mild adverse events were twice as frequent in the desipramine group as in the other groups. A predominantly noradrenergic tricyclic antidepressant induced a more intense short‐term effect on parkinsonian depression than did an SSRI. However, desipramine's lower tolerability may outweigh its slight short‐term clinical advantage. © 2008 Movement Disorder Society</abstract><qualityIndicators><score>6.57</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1434</abstractCharCount><pdfWordCount>4230</pdfWordCount><pdfCharCount>27948</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>195</abstractWordCount></qualityIndicators><title>Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study</title><genre><json:string>article</json:string></genre><host><volume>23</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>8</total><last>857</last><first>850</first></pages><issn><json:string>0885-3185</json:string></issn><issue>6</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2008</publicationDate><copyrightDate>2008</copyrightDate><doi><json:string>10.1002/mds.21966</json:string></doi><id>06154D74D83A89BE5059BABDAB5AF0211C913E45</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/06154D74D83A89BE5059BABDAB5AF0211C913E45/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/06154D74D83A89BE5059BABDAB5AF0211C913E45/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/06154D74D83A89BE5059BABDAB5AF0211C913E45/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2008</date></publicationStmt><notesStmt><note>“Projet Hospitalier de Recherche Clinique”</note><note>French Ministry of Health</note><note>“France Parkinson” charity</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study</title><author><persName><forename type="first">David</forename><surname>Devos</surname></persName><roleName type="degree">MD, PhD</roleName><note type="correspondence"><p>Correspondence: Hôpital R. Salengro, Clinique Neurologique, CHRU, F‐59037 LILLE Cedex, France</p></note><affiliation>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</affiliation></author><author><persName><forename type="first">Kathy</forename><surname>Dujardin</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</affiliation></author><author><persName><forename type="first">Isabelle</forename><surname>Poirot</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurophysiology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</affiliation></author><author><persName><forename type="first">Caroline</forename><surname>Moreau</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</affiliation></author><author><persName><forename type="first">Olivier</forename><surname>Cottencin</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Psychiatry, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</affiliation></author><author><persName><forename type="first">Pierre</forename><surname>Thomas</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Department of Psychiatry, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</affiliation></author><author><persName><forename type="first">Alain</forename><surname>Destée</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</affiliation></author><author><persName><forename type="first">Regis</forename><surname>Bordet</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Department of Pharmacology, IFR 114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</affiliation></author><author><persName><forename type="first">Luc</forename><surname>Defebvre</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-04-30"></date><biblScope unit="volume">23</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="850">850</biblScope><biblScope unit="page" to="857">857</biblScope></imprint></monogr><idno type="istex">06154D74D83A89BE5059BABDAB5AF0211C913E45</idno><idno type="DOI">10.1002/mds.21966</idno><idno type="ArticleID">MDS21966</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2008</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD). Recent reviews have highlighted the lack of controlled trials and the ensuing difficulty in formulating recommendations for antidepressant use in PD. We sought to establish whether antidepressants provide real benefits and whether tricyclic and selective serotonin reuptake inhibitor (SSRI) antidepressants differ in their short‐term efficacy, because the time to onset of therapeutic benefit remains an important criterion in depression. The short‐term efficacy (after 14 and 30 days) of two antidepressants (desipramine, a predominantly noradrenergic reuptake inhibitor tricyclic and citalopram, a SSRI) was assessed in a double‐blind, randomized, placebo‐ controlled study of 48 nondemented PD patients suffering from major depression. After 14 days, desipramine prompted an improvement in the Montgomery Asberg Depression Rating Scale (MADRS) score, compared with citalopram and placebo. Both antidepressants produced significant improvements in the MADRS score after 30 days. Mild adverse events were twice as frequent in the desipramine group as in the other groups. A predominantly noradrenergic tricyclic antidepressant induced a more intense short‐term effect on parkinsonian depression than did an SSRI. However, desipramine's lower tolerability may outweigh its slight short‐term clinical advantage. © 2008 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>depression</term></item><item><term>Parkinson's disease</term></item><item><term>antidepressant treatment</term></item><item><term>serotonin</term></item><item><term>norepinephrine</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2007-11-12">Received</change><change when="2008-01-13">Registration</change><change when="2008-04-30">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/06154D74D83A89BE5059BABDAB5AF0211C913E45/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="60"><doi origin="wiley" registered="yes">10.1002/mds.v23:6</doi><numberingGroup><numbering type="journalVolume" number="23">23</numbering><numbering type="journalIssue">6</numbering></numberingGroup><coverDate startDate="2008-04-30">30 April 2008</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="120" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.21966</doi><idGroup><id type="unit" value="MDS21966"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2008 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2007-11-12"></event><event type="manuscriptRevised" date="2008-01-09"></event><event type="manuscriptAccepted" date="2008-01-13"></event><event type="firstOnline" date="2008-02-29"></event><event type="publishedOnlineFinalForm" date="2008-04-24"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2008-02-29"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">850</numbering><numbering type="pageLast">857</numbering></numberingGroup><correspondenceTo>Hôpital R. Salengro, Clinique Neurologique, CHRU, F‐59037 LILLE Cedex, France</correspondenceTo><objectNameGroup><objectName elementName="figure">Illustration</objectName></objectNameGroup><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS21966.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="3"></count><count type="referenceTotal" number="39"></count><count type="wordTotal" number="5404"></count></countGroup><titleGroup><title type="main" xml:lang="en">Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study</title><title type="short" xml:lang="en">Depression in Parkinson's Disease</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>David</givenNames><familyName>Devos</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email normalForm="d-devos@chru-lille.fr">d‐devos@chru‐lille.fr</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Kathy</givenNames><familyName>Dujardin</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Isabelle</givenNames><familyName>Poirot</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Caroline</givenNames><familyName>Moreau</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Olivier</givenNames><familyName>Cottencin</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Pierre</givenNames><familyName>Thomas</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Alain</givenNames><familyName>Destée</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Regis</givenNames><familyName>Bordet</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Luc</givenNames><familyName>Defebvre</familyName><degrees>MD, PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="FR" type="organization"><unparsedAffiliation>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="FR" type="organization"><unparsedAffiliation>Department of Neurophysiology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="FR" type="organization"><unparsedAffiliation>Department of Psychiatry, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="FR" type="organization"><unparsedAffiliation>Department of Pharmacology, IFR 114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">depression</keyword><keyword xml:id="kwd2">Parkinson's disease</keyword><keyword xml:id="kwd3">antidepressant treatment</keyword><keyword xml:id="kwd4">serotonin</keyword><keyword xml:id="kwd5">norepinephrine</keyword></keywordGroup><fundingInfo><fundingAgency>“Projet Hospitalier de Recherche Clinique”</fundingAgency></fundingInfo><fundingInfo><fundingAgency>French Ministry of Health</fundingAgency></fundingInfo><fundingInfo><fundingAgency>“France Parkinson” charity</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD). Recent reviews have highlighted the lack of controlled trials and the ensuing difficulty in formulating recommendations for antidepressant use in PD. We sought to establish whether antidepressants provide real benefits and whether tricyclic and selective serotonin reuptake inhibitor (SSRI) antidepressants differ in their short‐term efficacy, because the time to onset of therapeutic benefit remains an important criterion in depression. The short‐term efficacy (after 14 and 30 days) of two antidepressants (desipramine, a predominantly noradrenergic reuptake inhibitor tricyclic and citalopram, a SSRI) was assessed in a double‐blind, randomized, placebo‐ controlled study of 48 nondemented PD patients suffering from major depression. After 14 days, desipramine prompted an improvement in the Montgomery Asberg Depression Rating Scale (MADRS) score, compared with citalopram and placebo. Both antidepressants produced significant improvements in the MADRS score after 30 days. Mild adverse events were twice as frequent in the desipramine group as in the other groups. A predominantly noradrenergic tricyclic antidepressant induced a more intense short‐term effect on parkinsonian depression than did an SSRI. However, desipramine's lower tolerability may outweigh its slight short‐term clinical advantage. © 2008 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Depression in Parkinson's Disease</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study</title></titleInfo><name type="personal"><namePart type="given">David</namePart><namePart type="family">Devos</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</affiliation><description>Correspondence: Hôpital R. Salengro, Clinique Neurologique, CHRU, F‐59037 LILLE Cedex, France</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kathy</namePart><namePart type="family">Dujardin</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Isabelle</namePart><namePart type="family">Poirot</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurophysiology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Caroline</namePart><namePart type="family">Moreau</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Olivier</namePart><namePart type="family">Cottencin</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Psychiatry, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Pierre</namePart><namePart type="family">Thomas</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Psychiatry, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alain</namePart><namePart type="family">Destée</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Regis</namePart><namePart type="family">Bordet</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Pharmacology, IFR 114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Luc</namePart><namePart type="family">Defebvre</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2008-04-30</dateIssued><dateCaptured encoding="w3cdtf">2007-11-12</dateCaptured><dateValid encoding="w3cdtf">2008-01-13</dateValid><copyrightDate encoding="w3cdtf">2008</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">2</extent><extent unit="tables">3</extent><extent unit="references">39</extent><extent unit="words">5404</extent></physicalDescription><abstract lang="en">Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD). Recent reviews have highlighted the lack of controlled trials and the ensuing difficulty in formulating recommendations for antidepressant use in PD. We sought to establish whether antidepressants provide real benefits and whether tricyclic and selective serotonin reuptake inhibitor (SSRI) antidepressants differ in their short‐term efficacy, because the time to onset of therapeutic benefit remains an important criterion in depression. The short‐term efficacy (after 14 and 30 days) of two antidepressants (desipramine, a predominantly noradrenergic reuptake inhibitor tricyclic and citalopram, a SSRI) was assessed in a double‐blind, randomized, placebo‐ controlled study of 48 nondemented PD patients suffering from major depression. After 14 days, desipramine prompted an improvement in the Montgomery Asberg Depression Rating Scale (MADRS) score, compared with citalopram and placebo. Both antidepressants produced significant improvements in the MADRS score after 30 days. Mild adverse events were twice as frequent in the desipramine group as in the other groups. A predominantly noradrenergic tricyclic antidepressant induced a more intense short‐term effect on parkinsonian depression than did an SSRI. However, desipramine's lower tolerability may outweigh its slight short‐term clinical advantage. © 2008 Movement Disorder Society</abstract><note type="funding">“Projet Hospitalier de Recherche Clinique”</note><note type="funding">French Ministry of Health</note><note type="funding">“France Parkinson” charity</note><subject lang="en"><genre>Keywords</genre><topic>depression</topic><topic>Parkinson's disease</topic><topic>antidepressant treatment</topic><topic>serotonin</topic><topic>norepinephrine</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>850</start><end>857</end><total>8</total></extent></part></relatedItem><identifier type="istex">06154D74D83A89BE5059BABDAB5AF0211C913E45</identifier><identifier type="DOI">10.1002/mds.21966</identifier><identifier type="ArticleID">MDS21966</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2008 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002379 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002379 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:06154D74D83A89BE5059BABDAB5AF0211C913E45
|texte= Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study
}}
| This area was generated with Dilib version V0.6.23. |  |